Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma Meeting Abstract
| Authors: | Fanucci, K.; Pilat, M. J. P.; Shah, R.; Boerner, S. A.; Li, J.; Durecki, D. E.; Drappatz, J.; Collichio, F. A.; Puduvalli, V. K.; Lieberman, F. S.; Gonzalez, J.; Giglio, P.; Bao, X.; Ivy, S. P.; Bindra, R.; Omuro, A. M. P.; LoRusso, P. |
| Abstract Title: | Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300686 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.2035 |
| Notes: | Meeting Abstract: 2035 -- This meeting was also held virtually -- Source: Wos |
